EyePoint Pharmaceuticals Announces Participation at Upcoming Investor Conferences

Rhea-AI Summary

EyePoint Pharmaceuticals (NASDAQ: EYPT) is set to present at two upcoming virtual conferences in March 2021. The first event is the Cowen Healthcare Conference on March 3, from 2:40-3:10 PM Eastern Time, featuring a fireside chat. The second event is the H.C. Wainwright Global Life Sciences Conference on March 9, at 7:00 AM Eastern Time, with a formal presentation. Investors can access a live webcast and archived replay on the company’s website for 90 days post-event. EyePoint focuses on therapeutics for serious eye disorders, leveraging Durasert® technology and offering products like YUTIQ® and DEXYCU®.

News Market Reaction – EYPT

-1.99%

-1.99% Session move

In the trading session that priced this news, EYPT declined 1.99%, reflecting a mild negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

WATERTOWN, Mass., Feb. 25, 2021 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to help improve the lives of patients with serious eye disorders, today announced that management will present at two upcoming virtual conferences in March.

Cowen Healthcare Conference
Forum: Fireside Chat
Date: Wednesday, March 3
Time: 2:40-3:10 PM Eastern Time

H.C. Wainwright Global Life Sciences Conference
Forum: Formal Presentation
Date: Tuesday, March 9
Time: 7:00AM Eastern Time

A live webcast and subsequent archived replay of the presentations may be accessed via the Investors section of the Company website at www.eyepointpharma.com. The replay will be available for 90 days after the event.

About EyePoint Pharmaceuticals

EyePoint Pharmaceuticals, Inc. (Nasdaq:EYPT) is a pharmaceutical company committed to developing and commercializing innovative therapeutics to help improve the lives of patients with serious eye disorders. The Company's pipeline leverages its proprietary Durasert^® technology for extended intraocular drug delivery including EYP-1901, a potential twice-yearly sustained delivery intravitreal anti-VEGF treatment initially targeting wet age-related macular degeneration. The Company has two commercial products: YUTIQ^®, for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye, and DEXYCU^®, for the treatment of postoperative inflammation following ocular surgery. EyePoint Pharmaceuticals is headquartered in Watertown, Massachusetts. To learn more about the Company, please visit www.eyepointpharma.com and connect on Twitter and LinkedIn.

FAQ

What are the dates for EyePoint Pharmaceuticals' presentations in March 2021?

EyePoint Pharmaceuticals will present at the Cowen Healthcare Conference on March 3 and at the H.C. Wainwright Global Life Sciences Conference on March 9, 2021.

What time will EyePoint Pharmaceuticals present at the Cowen Healthcare Conference?

EyePoint Pharmaceuticals will present at the Cowen Healthcare Conference on March 3, 2021, from 2:40 to 3:10 PM Eastern Time.

Where can I watch EyePoint Pharmaceuticals' conference presentations?

You can watch EyePoint Pharmaceuticals' conference presentations via live webcast on their website, with an archived replay available for 90 days.

What is EyePoint Pharmaceuticals' focus in the pharmaceutical industry?

EyePoint Pharmaceuticals focuses on developing and commercializing therapeutics for serious eye disorders, utilizing its Durasert® technology.

What products does EyePoint Pharmaceuticals offer?

EyePoint Pharmaceuticals offers two commercial products: YUTIQ® for chronic non-infectious uveitis and DEXYCU® for postoperative inflammation.